News

dentist

Dentist arrested for running over woman 2 wks ago | Delhi News

New Delhi: Two weeks after a 38-year-old woman was killed in a road accident in south Delhi’s Lado Sarai, a dentist with a private clinic in Saket has been arrested for allegedly mowing her down and fleeing from the spot.
The victim, who used to work with a private bank as a customer associate and lived on rent in Lado Sarai, was hit while crossing the road.
Police had received a call on November 17 about the accident at the Lado Sarai traffic signal. On reaching the spot, they found the woman, originally from Allahabad in Uttar Pradesh, to be critically injured. She was taken to AIIMS where she was declared brought dead.
On November 26, the victim’s brother tweeted, “I lost my sister, Archana Kushwaha, in an accident on 17th Nov at Lado Sarai Signal Delhi around 8.30PM, till now no clue about car and it’s being 10 days since accident happened (sic).” He also tagged the Prime Minister’s Office, AAP and Delhi Police.
On the day of the accident, crime and forensic teams visited the spot while the victim’s body was sent for a postmortem and her family was informed.
Deputy commissioner of police (south) Atul Thakur said a case of rash driving and causing death due to negligence was registered and a hunt was launched for the accused.
“Multiple teams were formed and CCTV footage from the vicinity were scanned. Following days of surveillance, we zeroed in on a Honda City car and its driver was identified as Pankaj Sudhakar, a resident of Kalkaji Extension,” Thakur said.
The DCP said Sudhakar was driving at a high speed. The accused might have been drunk during the accident, said a source. The car has been seized.

Source Article

Read More
medicine

Regenerative Medicine Market Size, Share to Amass Significant Gains During 2020-2025 – Industry News

The MarketWatch News Department was not involved in the creation of this content.

Dec 01, 2020 (Market Insight Reports) —
Selbyville, Delaware. The report Regenerative Medicine Market Size and Analysis maintains enhanced dynamics and is overshadowed by a top player across the globe. The research report provides Regenerative Medicine Market Growth and information corresponding to market segments such as geographies, product type, application, and end-use industry. Experts use the most recent Regenerative Medicine Market research techniques and tools to assemble widespread and precise marketing research reports. A detailed outline about Regenerative Medicine market size and share were combined in this report which gives a comprehensive analysis of different verticals of businesses.

The prevalence of diseases Alzheimera??s, diabetes and other chronic disorders is higher among the aging population across the globe. The incidence of diseases is getting increased day by day among the population. According to the Alzheimera??s Association, it is the 6th leading cause in the United States in 2020 and around 5 million individuals are living with Alzheimera??s. The use of regenerative medicine is getting popular and offers a complete cure from the disease. According to research report a??Global Regenerative Medicine Market Analysis, 2020a??, the Global Regenerative Medicine market is anticipated to grow at a CAGR of around 21.5% during 2020-25.

Request a sample Report of Regenerative Medicine Market [email protected] https://www.marketstudyreport.com/request-a-sample/2767182/?utm_source=marketwatch.com&utm_medium=ADS

Global Regenerative Medicine Market Analysis, 2020 research report depicts a deep dive market analysis of statistics of Global Regenerative Medicine market which consists of regional and country-wise market size, forecast, CAGR market segmentation, market shares of diverse regions and countries, market share of various end-users, applications, product type, technologies, competitive benchmarking, etc.

Pharmaceutical Remains a Dominant Sector

The pharmaceutical sector witnessed immense growth opportunities as more and more companies are indulging in research and studies for regenerative medicine in 2019. Vertex Pharmaceuticals Incorporated in 2018 got approval by FDA for launching their third medicine SYMDEKO for cystic fibrosis (CF) which is a genetic disorder affects liver, kidneys, pancreas, intestine, and lungs. These developments are propelling the growth of regenerative medicine and are expected to witness bolstering demand through 2025 as revealed by the research report a??Global Regenerative Medicine Market Analysis, 2020a??.

Musculoskeletal Disorders is Gaining Pace Across the Globe

The rising occurrence of arthritis and orthopedic diseases among the aging population as well as in the young population. Therefore, musculoskeletal disorders grabbed the largest market share in 2019. Moreover, diseases such as diabetes are also common in the Asian subcontinent. Moreover, around 34.2 million people of all ages or 10.5% of the US population had diabetes in 2018. Approximately, 34.1 million adults aged 18 years or older or 13.0% of all US adults had diabetes, according to US National Diabetes Statistics.

According to the key players with a considerable market share in the Global Regenerative Medicine market include Novartis AG, Vericel, Stryker, Spark Therapeutics, Wright Medical, Pfizer, Abbott, Astra Zenca Ltd., Astellas Pharma Inc., Osiris Therapeutics, Mimedx Group, Organogenesis Inc., Athersys, Inc, Acelity Holdings, Inc, etc.

Key Questions

Read More
medicine

Ionis announces AstraZeneca’s initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol | News

CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), an important regulator of low-density lipoprotein cholesterol (LDL-C). PCSK9 is an enzyme that controls the number of LDL receptors on the surface of cells. People with genetic variations that reduce PCSK9 function have lower LDL-C levels in the blood and a lower risk for major cardiovascular events. ION449 is a LIgand Conjugated Antisense (LICA) medicine being developed by AstraZeneca as part of a collaboration between Ionis and AstraZeneca.

The Phase 2b, randomized, double-blind, placebo-controlled trial will enroll approximately 108 participants, aged 18-75, who have LDL-C levels between 70 and 190 mg/dL and are receiving moderate- or high-intensity statin therapy as defined by the American College of Cardiology/American Heart Association (ACC/AHA) guidelines on blood cholesterol management. The primary objective is to assess the effect of different doses of ION449 on LDL-C compared to placebo at Week 12 in patients taking baseline statin therapy.  The study will evaluate three dose levels of ION449 versus placebo, all administered once a month by subcutaneous injection. Safety and tolerability will be evaluated along with a number of secondary endpoints. Learn more about the trial at: https://clinicaltrials.gov/ct2/show/NCT04641299. 

In a Phase 1 study reported at the American Heart Association (AHA) Scientific Sessions on November 13, single subcutaneous doses of ION449 (AZD8233) demonstrated dose-dependent mean reductions in circulating plasma PCSK9 and LDL-C levels of >90 percent and up to 70 percent, respectively, in subjects who had a baseline LDL-C between 100 and 190 mg/dL without concomitant statin therapy. Doses up to 120 mg were evaluated. ION449 was observed to be safe and well-tolerated at all dose levels. 

“Results from the Phase 1 study showed that ION449 potently reduces PCSK9 and LDL cholesterol. ION449 demonstrated best-in-class potential for PCSK9 inhibition and LDL-C reduction, supporting larger clinical trials that are now underway to further evaluate efficacy and safety,” said Sotirios “Sam” Tsimikas, M.D., senior vice president, clinical development and cardiovascular franchise leader at Ionis. “The growing evidence supporting Ionis’ advanced LICA technology in cardiovascular disease holds promise for more effective approaches to lower LDL-C and to address cardiovascular disease, the leading cause of death worldwide.”

Dr. Tsimikas will provide an update on Ionis’ cardiovascular programs during Ionis’ Virtual Investor Day, Dec. 7, 2020, beginning at 12 p.m. EST.

Ionis earned a milestone payment of $20 million from AstraZeneca for the Phase 2b clinical trial initiation of ION449. Ionis and AstraZeneca are collaborating on potential treatments for kidney disease, cardiometabolic disease and cancer.

About Ionis Pharmaceuticals, Inc.

As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our

Read More
medicine

Stanford Medicine begins enrolling for COVID-19 vaccine trial | News Center

Stanford Medicine has joined a large, Phase 3 clinical trial of an experimental vaccine against COVID-19.

The trial will test whether the vaccine, which is produced by the Janssen Pharmaceutical Companies of Johnson & Johnson, protects people from the disease. It will enroll some 60,000 people at about 180 sites around the world. The Stanford site is expected to enroll about 1,000 participants.  

Participants will receive either the vaccine or a placebo, and their health and immune responses will be monitored for about one year after their initial visits. If any participants become ill with symptoms of COVID-19, a health care provider will go to their homes to assess their health and collect a nasal sample to test for the presence of the novel coronavirus. If they are infected, Stanford physicians will monitor their disease progression. 

“We’re enrolling a wide variety of participants, but we are particularly interested in those who feel like their home or workplace exposure puts them at risk,” said Philip Grant, MD, assistant professor of medicine and the trial’s principal investigator at Stanford. “Teachers, grocery store workers, people who live in multigenerational households, health care workers and students on campus would all be good candidates for participation.”

Participants will be followed for two years and one month. They are expected to visit the trial site eight times: six in the first year and two in the second year. The initial visit will last about two hours; subsequent visits will consist of a short blood draw and symptom screening. If a participant develops COVID-19 during the study period, additional visits may be required.

Source Article

Read More
dentist

Lawsuit claims video shows Bishop’s Falls guards assaulting unconscious inmate in dentist’s chair | Canada | News

An inmate at a central Newfoundland prison is filing multiple lawsuits, including against corrections officers and a Gander oral surgeon, following an incident that reportedly happened at the surgeon’s office.

The Telegram has learned the man — an inmate at Bishops Falls Corrections Centre whose name is not being made public yet — alleges he was medically sedated at the oral surgeon’s office last month, when a corrections officer was video-recorded performing a dental procedure on him.

The video is believed to have been taken by another corrections officer, while two dental assistants were in the room at one point of the procedure.

The two corrections officers, who took the inmate to the oral surgeon’s office for an undisclosed procedure, were recently escorted out of the Bishop’s Falls facility by RCMP officers, a source told The Telegram earlier this week.

On Tuesday, both the RCMP and the Justice Department turned down requests for comment.

“My first reaction was shock and disbelief. With all due respect to my client. I thought it was incomprehensible and thought maybe he misapprehended what had happened.”

However, when contacted by The Telegram Wednesday, St. John’s lawyer Bob Buckingham confirmed he has been retained to represent the inmate and will file the lawsuit “fairly quickly” on his behalf.

“I haven’t heard of this happening in recent times in Newfoundland,” Buckingham said.

He said the lawsuits will claim battery, assault and breach of trust against the corrections officers; professional negligence and a breach of contract against the oral surgeon and the oral surgeon’s office; breach of trust by the corrections services and the provincial government, as well as vicarious liability against the provincial government, as it is alleged to have happened while corrections officers were on duty.

Buckingham said his client was unconscious at the time of the alleged incident, having been medically sedated, and had no knowledge of what happened when he left the dentist’s office a short time later. He said he learned about it and the video later from corrections administration.

“He understands one of the corrections officers took a video of this, which made the rounds within corrections services,” said Buckingham, adding that both the corrections administration and the RCMP are in possession of the video.

Buckingham said he was appalled to hear what the inmate says happened to him.

“My first reaction was shock and disbelief,” he said. “With all due respect to my client, I thought it was incomprehensible and thought maybe he misapprehended what had happened.

“It’s a very difficult set of circumstances to believe, given a professional involving a dentist and corrections officers who were there for his protection, and the inmate being under medically induced sedation.

“But types of egregious breaches of trust do happen in our province,” added Buckingham, who also represents the family of Jonathan Henoche, an inmate who was killed in segregation at Her Majesty’s Penitentiary in November 2019, in lawsuits against the corrections officers, the prison and the provincial government.

He said

Read More
medicine

Precision medicine key to preventing disease developing later in life, Singapore News & Top Stories

SINGAPORE – An individual’s genes can determine the amount of risk he has of developing life-threatening conditions such as heart disease and in turn allows for early intervention.

This is central to the precision medicine programme here, said Professor Tan Chorh Chuan, the chief health scientist from the Ministry of Health and executive director at the Healthcare Transformation Office.

Prof Tan told a webinar on Wednesday (Nov 25) that the programme looks at the genome sequences of participants to help determine the cumulative risks of different diseases based on their genes.

This can be particularly useful for some complaints like premature heart disease, added Prof Tan, who was joined on the webinar panel by Prudential chief executive Dennis Tan and Health Promotion Board (HPB) CEO Zee Yoong Kang.

The event, which covered a broad range of health topics from diabetes and vaccines to strategies on how to stay healthy, is part of The Straits Times Reset 2021 webinar series. It was sponsored by Prudential and moderated by ST senior health correspondent Salma Khalik.

Prof Tan told the webinar that a condition known as familial hypercholesterolemia is caused when a person has a gene that results in high cholesterol levels at a much younger age. If that gene is present, the individual will have up to 20 times higher risk of heart disease – and at an earlier age.

“And then if we identify somebody, we can also test the family. So these preventive strategies will be part of precision health,” he added.

The HPB is working to make use of the clinical, behavioural and digital data as well as genetic data – with patient consent – to identify those at higher risk to allow for early intervention.

Prudential’s Mr Tan said Singaporeans need not be worried about being part of the programme or be concerned if they find out their genome sequences. Having “bad” genes will not make it harder for them to secure insurance policies, he assured.

Privacy is really important, Mr Tan said, adding that “we (Prudential) are very, very careful about such things”.

He said individuals ultimately have to take charge of their own health and should find out more. He said: “Preventive healthcare is all about them being in the driver’s seat, and going through the whole process of early detection, health screening and all.

“So I think as insurers, we will definitely support them.”

Ms Khalik noted that if a person learns that he is at a high risk of getting a certain disease, it will give him the time and opportunity to act before the ailment takes hold.

Source Article

Read More
medicine

Does Health Insurance Cover Concierge Medicine? |U.S. News

Does health insurance cover concierge medicine? Are there strategies for getting the most out of your health insurance with respect to concierge medicine?

(Getty Images)

The answers are: sometimes, and yes.

How Concierge Medicine Works

Concierge medicine is a heath care model in which a patient pays a fee – monthly, biannually or annually – directly to their doctor for the practice’s services. Under this model, consumers have access to their doctor or another physician in the practice whenever they want. Patients can make same-day appointments with little or no waiting.

This framework is similar to an arrangement of a client who keeps an attorney on retainer. Such clients can obtain legal services whenever they need them and don’t pay by the hour or case.

Concierge Medicine Costs

As for costs, the annual fee to subscribe to most concierge medicine practices ranges between $1,200 and $3,000, according to conciergemedicinetoday.org. Some high-end concierge medicine practices that provide services to well-off patients can cost tens of thousands of dollars a year, experts say.

Here is the breakdown of payment options that concierge medicine practices accept, according to conciergemedicinetoday.org:

  • Cash only, 51%
  • Medicare or some insurance, 29%
  • Medicare but no HMO or PPO plans, 14%
  • Insurance but no Medicare, 6%

What Health Insurance Does and Does Not Cover

Here are the ways you can use health insurance for concierge medicine:

Medicare or some insurance. If you have Medicare or other health insurance, you can join a concierge medical practice, but you’ll have to pay the membership fee yourself. Regarding Medicare, a concierge medical practice “can’t include additional charges for items or services that Medicare usually covers unless Medicare won’t pay for the item or service,” according to Medicare.gov. In those situations, your physician must give you a written notice, known as an “Advance Beneficiary Notice of Noncoverage,” listing the services and reasons why Medicare may not pay. In such situations, a concierge practice may seek to impose additional fees for services not covered by Medicare, says Michael Seavers, the program lead in Healthcare Informatics at Harrisburg University of Science and Technology in Harrisburg, Pennsylvania. He notes that Medicare isn’t only used by older people. Individuals under age 65 with certain medical conditions, like renal failure, may also qualify for Medicare.

Similarly, if you have private health insurance, you must pay the fee yourself to become a patient in a concierge practice, says Dr. Amna Husain, a pediatrician and the founder of Pure Direct Pediatrics. That’s a concierge practice in Marlboro, New Jersey. “This fee will include the normal care you received from a non-concierge doctor with the added personal medical amenities the concierge practice offers,” she says.

You may be able to use Medicare or other health insurance to pay for items and services the concierge practice doesn’t provide, which can include:

  • Prescription medications.
  • Lab work.
  • Imaging.
  • Emergency department visits and hospitalizations.

Doctors who accept assignment can’t charge you extra for Medicare-covered services. (In the context of Medicare, “assignment” means your health

Read More
fitness

Liverpool manager Jurgen Klopp eager for good news as Naby Keita suffers injury

Jurgen Klopp has more injury worries
Jurgen Klopp has more injury worries

Liverpool manager Jurgen Klopp will be hoping for some good news on the fitness of midfielders Thiago Alcantara and Jordan Henderson in the next 24 hours after being struck down by yet more injury problems.

The defending Premier League champions underlined their enduring quality and will to win with a comfortable 3-0 victory over Leicester – setting a new club record of 64 unbeaten league matches at home – despite missing 10 members of his first-team squad.

But just as Klopp got Fabinho back from a three-week lay-off with a hamstring problem to play as an emergency centre-back he lost fellow midfielder Naby Keita to a similar injury.

And midfielder Xherdan Shaqiri did not even make the squad after it was discovered he had returned from international duty with yet another muscle problem.

With Wednesday’s Champions League visit of Atalanta offering the chance to secure qualification to the knockout phase with two matches still to play Klopp will hope either or both of Henderson, who came back from England duty with a thigh problem, and Thiago, having been sidelined by a knee problem since mid-October, can be available as he is still without Alex Oxlade-Chamberlain, who has not played after a knee injury in pre-season.

Without him his midfield options look fairly slim as, with James Milner filling in at right-back for the injured Trent Alexander-Arnold, 19-year-old academy graduate Leighton Clarkson made his first appearance in a match day squad against the Foxes after they learned of Shaqiri’s unavailability.

“Shaq had a muscle injury with the national team which he didn’t really realise,” said Klopp.

“He trained with us, we gave him a day off and then he came back and was involved in the session, but was not fully involved.

“After that he felt a little bit (of a problem). Then we did a scan and they found he has an injury from five or six days ago.

“Nobody knew about that, not even Shaq knew about it, but that’s how things sometimes are and so he was not able to be involved.

Mohamed Salah is likely to return to the squad after a negative Covid-19 test having tested positive on international duty with Egypt but in his absence summer signing Diogo Jota continued his hot streak.

A seventh goal in his last six club appearances saw him become the first Liverpool player to score in his first four home top-flight appearances.

“Yes, he’s a good player – that’s the reason why we signed him,” was Klopp’s assessment.

Leicester manager Brendan Rodgers has injury problems of his own, although not to the extent of his successor at Liverpool.

He had hoped to have left-back Timothy Castagne back for the trip to Anfield but the Belgium international suffered a minor set-back in his recovery from a thigh injury.

“He had a few good

Read More
medicine

SPORTS MEDICINE: Take heart from latest COVID-19-related news | John Doherty

Dr. Sean Swearingen is a cardiologist with Community Care Network in Munster, who works with the athletic department at Purdue Northwest. He explained what “mild” symptoms of COVID-19 are and what they are not.

“It is symptoms that are not in any way inhibiting their day-to-day function and they are for less than 10 days,” he said, “then that is what falls in the category of mild symptoms and they don’t need any further cardiac workup. From the patients I have (had tested), they haven’t had to be hospitalized but they have had relatively significant symptoms where they have been out of commission for several days, haven’t been able to attend their online classes (because) they’ve been so fatigued. To me, I would consider that moderate symptoms.”

Symptomatic or not, cardiac tested or not, all athletes who have been diagnosed with COVID-19 need to be cautious as they return to sport, according to Swearingen.

While I questioned the Big Ten’s 21-day minimum in comparison to the ACC’s 10-day minimum in this space earlier this month, Swearingen finds it more than reasonable.

“The 21-day Big Ten protocol (allows) for a week-long ramp period in the final week,” he explained. “I am a big supporter of this — a gradual monitored increase in activity allows for another layer of safety so that players can be monitored for signs and symptoms before they are putting themselves at risk in full-on competition. The monitored physical activity is just as important as the testing itself and it seems like a lot of people are ignoring that final part in the guideline, the gradual increase in activity.”

Source Article

Read More
dentist

Court dismisses dentist’s appeal over tax on earnings, Singapore News & Top Stories

The High Court has dismissed a dentist’s appeal that he should be charged the corporate tax rate for earnings paid to a company he created, finding his main goal in setting it up was to avoid tax.

Justice Choo Han Teck ruled in the first such case to go on appeal to the High Court that Dr Wee Teng Yau’s move would enable him to pay less tax on the same services he provided.

This is because his fees paid into the company would be its income and taxed at the lower corporate tax rate. But if the fees had been paid directly to him, the personal income tax rate – which is higher – would be levied.

Justice Choo’s ruling pivots on a provision in the Income Tax Act, according to judgment grounds released earlier this month.

The provision at issue is Section 33 of the Act.

The tax authorities said last week that Section 33 has been applied to more than 100 medical professionals.

Referring to the section, Justice Choo said it is meant to cover arrangements created by the taxpayer to reduce the taxes which he would otherwise have to pay.

The judge found in this case “the facts show (its) main, if not only, purpose was to enable Dr Wee to avoid tax. This is precisely the type of arrangement that is covered by Section 33(1)”.

The case is the first to be heard before the court as previous such appeals were not pursued beyond the Income Tax Board of Review.

Dr Wee was employed by dental clinic Alfred Cheng Orthodontic Clinic (ACOC) from January 2011 to May 2012.

He set up Straighten (SPL) in May 2012, and was its sole director and shareholder. He continued to provide the same dental services to ACOC’s patients, but ACOC made the payments to SPL instead of to him, the court noted.

SPL, in turn, paid him a salary and director’s fee. Tax-exempt dividends were also declared and paid to him from SPL’s profits.

For assessment year 2012, ACOC paid Dr Wee $279,194.60 in fees.

Between assessment years 2013 and 2016, the fees ACOC paid SPL and reported as SPL’s income totalled $1,470,764.

SPL paid $336,000 in director’s remuneration to Dr Wee who also received tax-exempt dividends totalling $765,205 as a shareholder.

Each year, the remuneration he received from SPL ranged between $40,000 and $110,000. This is significantly lower than the $279,194.60 he got as income in 2011 from ACOC, the court noted.

The Comptroller of Income Tax treated the fees SPL received from ACOC as Dr Wee’s income and imposed the personal income tax rate instead of the corporate tax rate as sought by Dr Wee.

The Income Tax Board of Review affirmed the Comptroller’s position and Dr Wee appealed further.

In the High Court, the Comptroller’s counsel Zheng Sicong and Serene Lau relied on Section 33(1) as the ground for the levy.

But Dr Wee’s lawyer Lau Kah Hee argued, among other things, that Dr Wee would

Read More